Mithrl raised $20 million in Series A funding led by Obvious Ventures to expand deployment of its biomedical world-model platform for accelerating discovery through IND. The company said Mithrl-1 combines a curated biology layer with agentic AI components for routing and token optimization, and it is rolling out early access for second-generation capabilities. Mithrl’s financing highlights continuing investor focus on compute-efficient “agentic” systems that can operate with validated biology rather than unbounded search. The startup also reported benchmark results showing reduced token usage compared with standard workflows using frontier base models. For R&D operators, the round points to a widening software stack around drug discovery execution—from hypothesis generation with source tracing to workflow integration intended to shorten time from idea to IND.